Proton Radiotherapy for Solid Tumors

(PARTy Trial)

No longer recruiting at 2 trial locations

Overseen By Hyun Kim, M.D.

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Washington University School of Medicine

Disqualifiers: Small cell carcinoma, Uncontrolled illness, Pregnant, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 5

Duration: 2 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method for planning proton radiotherapy for solid tumors, aiming to make treatment more precise and safe. The approach adjusts treatment plans on the day of therapy, considering any changes in a patient's anatomy, to optimize radiation effectiveness. This method could ensure patients receive the best possible treatment at each visit. Suitable candidates for this trial include individuals with a solid tumor cancer confirmed through biopsy or imaging and deemed healthy enough for this type of radiation by their doctor. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance future cancer treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What prior data suggests that this online adaptive planning technique is safe for proton radiation therapy?

Research has shown that proton stereotactic body radiotherapy (SBRT) is generally safe for treating solid tumors. In several studies, patients experienced only minor side effects. For instance, one study found that no patients suffered severe side effects, such as serious toxicity. Another study demonstrated that proton SBRT was effective and safe, even for larger tumors, without causing serious harm. These findings suggest that proton SBRT is a safe option for those considering this treatment. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about Proton Stereotactic Body Radiotherapy (SBRT) because it offers a highly precise approach to treating solid tumors by using proton beams instead of traditional X-rays. Unlike conventional radiation therapy, which can affect surrounding healthy tissue, proton therapy targets tumors with pinpoint accuracy, potentially reducing side effects. Additionally, the adaptive planning process in this treatment tailors each session to the patient's unique anatomy on the day of treatment, optimizing effectiveness and safety with every fraction delivered.

What evidence suggests that online adaptive planning for proton SBRT is effective for solid tumors?

Research has shown that proton stereotactic body radiation therapy (SBRT), which participants in this trial will receive, is a safe and effective treatment for solid tumors. Studies have found that proton SBRT controls tumors well, achieving success rates over 90% with high doses. One study noted 79.1% survival after one year and 73.8% after two years, indicating good patient survival rates. Proton therapy typically causes fewer side effects than traditional radiation, allowing it to target tumors more precisely while minimizing harm to healthy tissue. These findings suggest that proton SBRT is a promising option for effectively treating solid tumors. ^{6 7 8 9 10}

Who Is on the Research Team?

Michael Waters, M.D.

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

This clinical trial is open to individuals with solid tumors who are scheduled for proton radiation therapy. The study aims to test a new method of planning treatment on the same day as delivery, adjusting for any changes in patient anatomy.

Inclusion Criteria

Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, or a male suspect he has fathered a child, s/he must inform the treating physician immediately.

I have had radiation therapy before.

I am mostly able to care for myself and carry out normal activities.

Exclusion Criteria

Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of study entry.

I cannot undergo proton therapy due to medical reasons or my doctor thinks I'm not fit for SBRT.

I have another cancer, but it won't affect this trial's treatment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive proton stereotactic body radiotherapy (SBRT) with daily online adaptive planning for a total of 5 fractions

2 weeks

5 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on radiation-related toxicities

3 months

What Are the Treatments Tested in This Trial?

Interventions

• Proton SBRT

Trial Overview

The trial is testing online adaptive planning in proton SBRT (a type of targeted radiation therapy). It involves creating and possibly modifying a treatment plan directly before administering it, to ensure precision and safety.

How Is the Trial Designed?

Group I: Proton Stereotactic Body Radiotherapy (SBRT) Experimental Treatment 1 Intervention

All patients will receive standard of care proton SBRT either daily or every other day for a total of 5 fractions. At the time of each treatment, the initial pre-plan will be generated on the patient and assessed for coverage and safety. An adaptive plan based on the patient's anatomy that day will also be generated and then compared to the initial pre-plan. The optimal treatment plan will be chosen and administered to the patient on that day. This process will be repeated for each fraction for every patient.

Proton SBRT is already approved in United States, European Union, Japan, Canada for the following indications:

Approved in United States as Proton Radiation Therapy for:

• Various cancers including but not limited to brain, spine, lung, liver, pancreas, prostate, breast, and pediatric cancers

Approved in European Union as Proton Radiation Therapy for:

• Various cancers including but not limited to ocular melanoma, chordomas, chondrosarcomas, and pediatric cancers

Approved in Japan as Proton Radiation Therapy for:

• Various cancers including but not limited to prostate, lung, liver, and pediatric cancers

Approved in Canada as Proton Radiation Therapy for:

• Various cancers including but not limited to brain, spine, and pediatric cancers

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+

The Foundation for Barnes-Jewish Hospital

Collaborator

Trials

43

Recruited

6,600+

Published Research Related to This Trial

Stereotactic body proton therapy (SBPT) demonstrated effective local control rates for high-risk lung tumors, achieving 89% local control for early-stage non-small cell lung cancer (NSCLC) and 100% for locally recurrent NSCLC over three years, while maintaining excellent tumor coverage without compromising safety.

The treatment exhibited a favorable toxicity profile, with only 7.4% of patients experiencing significant pulmonary toxicity, and no severe toxicities related to other organs, suggesting SBPT is a promising option for patients with challenging lung tumors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors. McMillan, MT., Shepherd, AF., Kang, M., et al.[2023]

The study aimed to compare the efficacy and toxicity of stereotactic body radiation therapy (SBRT) and stereotactic body proton therapy (SBPT) in treating high-risk, medically inoperable early-stage non-small cell lung cancer, but it closed early due to low patient enrollment, with only 21 patients participating.

At a median follow-up of 32 months, the SBPT group showed promising results with a 90% three-year overall survival rate and 90% local control, while the SBRT group had a 27.8% three-year overall survival rate, indicating potential advantages of SBPT despite the study's limitations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Nantavithya, C., Gomez, DR., Wei, X., et al.[2022]

Stereotactic body proton therapy (SBPT) showed greater dose escalation potential compared to stereotactic body photon therapy (SBXT) in treating prostate cancer, particularly for larger prostate volumes, indicating it may be a more effective option for high-risk patients.

In a study of 25 patients, SBPT resulted in lower doses to critical structures like the bladder neck while still achieving significant target coverage, suggesting a safer treatment profile with potentially fewer side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Simulation of an HDR "Boost" with Stereotactic Proton versus Photon Therapy in Prostate Cancer: A Dosimetric Feasibility Study. Remick, JS., Sabouri, P., Zhu, M., et al.[2022]

Proton therapy (PT) and stereotactic body radiotherapy (SBRT) showed similar effectiveness in delivering doses to the planning target volume (PTV) for early-stage non-small-cell lung cancer, but PT generally resulted in lower doses to normal tissues, particularly the lungs.

Actively scanned proton therapy provided better dose characteristics compared to passively scattered plans, indicating a potential advantage in minimizing damage to surrounding healthy tissues, although the clinical significance of these differences needs further investigation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. Macdonald, OK., Kruse, JJ., Miller, JM., et al.[2022]

In a study involving 8 patients with early-stage non-small-cell lung cancer, proton-based stereotactic body radiotherapy (pSBRT) demonstrated significant dosimetric improvements over photon-based SBRT (xSBRT), reducing radiation exposure to normal lung tissue and critical organs like the heart and esophagus.

pSBRT resulted in lower doses to normal structures, with significant reductions in lung exposure at various dose levels (e.g., V5 and V10), suggesting a potential for reduced toxicity compared to xSBRT, although the clinical significance of these findings is still uncertain.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy. Hoppe, BS., Huh, S., Flampouri, S., et al.[2018]

Proton stereotactic body radiation therapy (SBRT) demonstrated a high local control rate of 92.5% for liver metastases in a study of 46 patients, with a median follow-up of 15 months.

The treatment was well-tolerated, with low toxicity rates (37% grade 1 and 6.5% grade 2), and no severe toxicities or cases of radiation-induced liver disease, indicating a safe profile for managing multiple liver lesions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions. Coffman, AR., Sufficool, DC., Kang, JI., et al.[2022]

In a study involving 15 patients with centrally or superiorly located stage I non-small-cell lung cancer (NSCLC), intensity-modulated proton therapy (IMPT) and passive-scattering proton therapy (PSPT) were found to significantly reduce radiation exposure to surrounding healthy tissues compared to conventional photon stereotactic body radiation therapy (SBRT).

IMPT and PSPT plans not only improved tumor coverage but also minimized the maximum tolerated dose to critical structures like the heart and spinal cord, demonstrating their potential for safer treatment options in patients with challenging tumor locations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Register, SP., Zhang, X., Mohan, R., et al.[2021]

In a study involving 12 patients, proton therapy (both passively scattered and intensity-modulated) showed similar target conformity to conventional photon therapy (3D-CRT) for hypofractionated stereotactic body radiotherapy, indicating comparable effectiveness in targeting lung lesions.

Proton therapy techniques significantly reduced radiation exposure to the heart and contralateral lung, achieving almost 0Gy to the heart compared to around 3Gy with photon therapy, suggesting potential safety benefits, although the clinical impact of these dosimetric advantages needs further investigation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Can protons improve SBRT for lung lesions? Dosimetric considerations. Georg, D., Hillbrand, M., Stock, M., et al.[2018]

Proton-based stereotactic body radiation therapy (SBRT) for liver metastases showed a one-year local control rate of 71.9% and was well tolerated, with no severe toxicities reported in a study of 89 patients over a median follow-up of 30.1 months.

KRAS mutations were identified as a significant predictor of poor local control, highlighting the importance of genetic testing before treatment to tailor approaches for patients with liver metastases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Hong, TS., Wo, JY., Borger, DR., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8421917/

Proton stereotactic body radiation therapy for liver ...

SBRT has been shown to be safe in dose escalation studies (15-18) with excellent control rates above 90% with biologically effective doses (BED) >100 Gy10 (19).

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S233151802500006X

Comparison of Proton Versus Photon SBRT for Treatment ...

Overall survival at 1 and 2 years was 79.1% and 73.8%. All patients were assessed during and following radiation therapy for acute and long-term toxicities.

3.

pfmjournal.org

pfmjournal.org/journal/view.php?doi=10.23838/pfm.2019.00058

Proton therapy: the current status of the clinical evidences

Studies from the MGH reported that the 5-year local relapse-free survival rates were 73% for chordoma and 98% for chondrosarcoma in 519 patients ...

4.

academic.oup.com

academic.oup.com/jnci/article/109/9/djx031/3852626

Phase II Study of Proton-Based Stereotactic Body Radiation ...

Protons were remarkably well tolerated and effective even for metastases that were 6 cm or larger. KRAS mutation is a strong predictor of poor ...

5.

jamanetwork.com

jamanetwork.com/journals/jamaoncology/fullarticle/2757520

Comparative Effectiveness of Proton vs Photon Therapy as ...

Concurrent chemoradiotherapy administered with proton therapy might reduce toxicity and achieve comparable cancer control outcomes compared with ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/28954285/

Phase II Study of Proton-Based Stereotactic Body ...

Protons were remarkably well tolerated and effective even for metastases that were 6 cm or larger. KRAS mutation is a strong predictor of poor ...

7.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC2952351/

PROTON STEREOTACTIC BODY RADIATION THERAPY ...

Stereotactic body radiation therapy (SBRT) appears to be as effective as surgery for these patients with medical inoperable early stage lung cancer, with local ...

8.

jgo.amegroups.org

jgo.amegroups.org/article/view/49396/html

Proton stereotactic body radiation therapy for liver metastases ...

Proton SBRT appears to be safe with no patients experiencing grade 3 or higher toxicity or RILD. This is significant considering 56.5% of patients completed ...

9.

sciencedirect.com

sciencedirect.com/science/article/pii/S2452109425000648

FLASH Stereotactic Body Radiation Therapy for Spine ...

BP-FLASH SBRT is a promising treatment for challenging spinal cord cancers, which achieved ultra-high-dose rates for FLASH effect and maintained the same ...

10.

astro.org

astro.org/astro/media/astro/daily%20practice/pdfs/astropbtmodelpolicy.pdf

Model Policies

Stereotactic Body Radiation Therapy (SBRT) ... Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural. Mesothelioma ...